It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-21 14:09:44 Source:healthViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Burglar hurled stolen mobile phones at police from the top of 60ft high roof during nine
Next:Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
You may also like
- Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry
- Türkiye's opposition takes election lead in key cities
- Paris prepares for 100
- Chinese heritage attracts Universiade athletes in Chengdu
- Rangers are undefeated at .500 to keep World Series champs from a losing record with Bochy
- 5 Chinese nationals, 1 Pakistani killed in terrorist attack in NW Pakistan
- Xizang chairman hails region's miraculous development
- Ukraine says Russian warship in Baltic Sea out of service after fire
- Britain's new bonkers EV: Callum Skye is an £80k electric buggy built in Warwickshire